244 related articles for article (PubMed ID: 30182850)
1. Therapeutic Macromolecular Iron Chelators.
Bulbake U; Singh A; Domb AJ; Khan W
Curr Med Chem; 2019; 26(2):323-334. PubMed ID: 30182850
[TBL] [Abstract][Full Text] [Related]
2. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
3. Design of clinically useful macromolecular iron chelators.
Zhou T; Winkelmann G; Dai ZY; Hider RC
J Pharm Pharmacol; 2011 Jul; 63(7):893-903. PubMed ID: 21635254
[TBL] [Abstract][Full Text] [Related]
4. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes GJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation therapy for transfusional iron overload: a swift evolution.
Musallam KM; Taher AT
Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
[TBL] [Abstract][Full Text] [Related]
6. New developments in iron chelators.
Cunningham MJ; Nathan DG
Curr Opin Hematol; 2005 Mar; 12(2):129-34. PubMed ID: 15725903
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
8. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox.
Stumpf JL
Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
[TBL] [Abstract][Full Text] [Related]
10. Design of iron chelators with therapeutic application.
Zhou T; Ma Y; Kong X; Hider RC
Dalton Trans; 2012 Jun; 41(21):6371-89. PubMed ID: 22391807
[TBL] [Abstract][Full Text] [Related]
11. Update on iron chelators in thalassemia.
Neufeld EJ
Hematology Am Soc Hematol Educ Program; 2010; 2010():451-5. PubMed ID: 21239834
[TBL] [Abstract][Full Text] [Related]
12. Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Bernhardt PV
Dalton Trans; 2007 Aug; (30):3214-20. PubMed ID: 17893764
[TBL] [Abstract][Full Text] [Related]
13. Polymeric nanocarriers for the treatment of systemic iron overload.
Hamilton JL; Kizhakkedathu JN
Mol Cell Ther; 2015; 3():3. PubMed ID: 26056604
[TBL] [Abstract][Full Text] [Related]
14. Synthetic and natural iron chelators: therapeutic potential and clinical use.
Hatcher HC; Singh RN; Torti FM; Torti SV
Future Med Chem; 2009 Dec; 1(9):1643-70. PubMed ID: 21425984
[TBL] [Abstract][Full Text] [Related]
15. Chelating agents for the treatment of systemic iron overload.
Ma Y; Zhou T; Kong X; Hider RC
Curr Med Chem; 2012; 19(17):2816-27. PubMed ID: 22455586
[TBL] [Abstract][Full Text] [Related]
16. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
18. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
19. Current and future treatment strategies for iron overload cardiomyopathy.
Wongjaikam S; Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
Eur J Pharmacol; 2015 Oct; 765():86-93. PubMed ID: 26291660
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
